coronary artery disease patient with in-stent neoatherosclerosis
Conditions
Interventions
Intensive lipid lowering therapy start with EPA and Rosuvastatin 10 mg/day and up to 20 mg/day
Standard lipid lowering therapy start with only Rosuvastatin 2.5 mg/day and up to 20 mg/day
Sponsors
Division of Cardiovascular Medicine, Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients meeting all of the following conditions will be included: AN detected by OCT >1 year after stent implantation (Include any type of stent [BMS, 1st generation DES, and 2nd generation DES]) between 20 and 85 years old written consent for participation in the study
Exclusion criteria
Exclusion criteria: Patients meeting one of the following conditions will be excluded: 1) severe liver dysfunction 2) renal dysfunction (<Cre 2.0mg/dL) 3) severe heart failure (NYHA/New York Heart Association stage III or severer) 4) malignancies or other diseases with poor prognosis 5) pregnant, lactating, and possibly pregnant women and those planning to become pregnant 6) past medical history of hypersensitivity to investigational drugs 7) judged as ineligible by clinical investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in lipid index analyzed by optical coherence tomography | — |
Secondary
| Measure | Time frame |
|---|---|
| Ischemic driven TLR, MACE(death, myocardial infarction, TLR), and stent thrombosis, other OCT parameters | — |
Countries
Japan
Contacts
Public ContactHiromasa Otake
Kobe University Graduate School of Medicine Division of Cardiovascular Medicine
Outcome results
None listed